Loading...
01/11 03:17
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call revealed mixed financial performance, with a significant operating loss and negative EBITDA largely due to the absence of last year's PRV sale. While there were improvements in gross margins, the temporary U.S. license suspension for IXCHIQ and unclear FDA timelines add uncertainty. The Q&A highlighted management's lack of specific guidance on key issues like IXCHIQ's suspension and DUKORAL's growth in Germany, leading to a negative sentiment. The absence of clear guidance and the mixed financial results suggest a likely negative stock price reaction.
Total revenues EUR 127 million at the 9-month time point, a growth of almost 9% year-over-year. Reasons for growth include overcoming geopolitical and IXCHIQ-related challenges.
Operating cash burn Significantly reduced, resulting in a cash position of more than EUR 140 million. This includes net proceeds from ATM transactions and debt refinancing.
Product sales EUR 119.4 million compared to EUR 112 million in the 9 months of 2024, an increase of 6.2%. Foreign currency fluctuation had an adverse impact of EUR 1.3 million.
IXIARO sales EUR 74.3 million, increasing 12.5% over the prior year. Growth driven by sales to the U.S. Department of Defense and increased sales in European countries. Adversely impacted by EUR 800,000 due to foreign currency fluctuation.
DUKORAL sales Decreased from EUR 22.3 million in the first 9 months of 2024 to EUR 21.5 million in 2025. Reasons include foreign currency fluctuation (EUR 400,000 impact) and lower sales to the German partner due to distributor transition.
IXCHIQ sales EUR 7.6 million compared to EUR 1.8 million in the 9 months of 2024. Growth includes supply of 40,000 doses for a chikungunya outbreak. Adversely impacted by temporary U.S. license suspension.
Third-party products Decreased by 28.5% year-over-year to EUR 16.1 million. Decline due to anticipated discontinuation of certain third-party distribution agreements.
Gross margin on commercial products (excluding IXCHIQ) 57.2% in the first 6 months of 2025 compared to 48.6% in the prior year. Improvement driven by better manufacturing performance and favorable product mix.
IXIARO gross margin 63.2% compared to 58.8% in the first 9 months of 2024. Improvement due to better manufacturing performance and product mix.
DUKORAL gross margin 52.3% compared to 34.8% in the prior year. Improvement due to better manufacturing performance and product mix.
Cost of goods related to IXCHIQ EUR 8.6 million, including provisions for lower demand and EUR 8.2 million of idle capacity costs.
Research and development expense Increased from EUR 48.6 million in the 9 months of 2024 to EUR 59.7 million in 2025. Increase driven by costs related to the Shigella vaccine candidate and IXCHIQ Phase IV post-marketing commitment.
Marketing and distribution expense Decreased from EUR 35.7 million in 2024 to EUR 28.6 million in 2025. Decrease due to planned reduction in advertising and promotion spend for IXCHIQ.
G&A expense EUR 29.5 million in the first 9 months of 2025 compared to EUR 32.6 million in 2024. Decrease due to a program to increase operational efficiency.
Operating loss EUR 53.9 million compared to an operating profit of EUR 34.2 million in 2024. Last year's profit was due to a sale of a Priority Review Voucher for EUR 90.8 million.
Adjusted EBITDA Negative EUR 37.7 million compared to a positive EUR 48.6 million in 2024. Impacted by the absence of the PRV sale.
Cash position EUR 143.5 million at September 30, 2025, compared to EUR 168.4 million at the end of 2024. Includes EUR 26 million from ATM transactions. Cash used in operating activities was EUR 28.4 million compared to EUR 76.7 million in 2024.
Lyme Disease Vaccine (VLA15): Phase III study ongoing with Pfizer, regulatory applications expected in 2026, and product launch planned for autumn 2027. The vaccine addresses a major unmet medical need with a significant market opportunity.
Chikungunya Vaccine (IXCHIQ): Sales reached EUR 7.6 million, supported by outbreak response in La Réunion. Regulatory challenges in the U.S. persist, but expansion into LMIC territories is underway. Positive data on antibody persistence and pediatric safety reported.
Shigella Vaccine (S4V2): Phase II studies ongoing, targeting infants and adults. Positive earlier clinical data reported. Represents a significant opportunity for LMICs, travelers, and military.
Zika Vaccine (VLA1601): Reported positive Phase I results.
Market Expansion for IXCHIQ: Secured additional marketing authorizations in the U.K. and Brazil. Label extensions for adolescents in Europe and Canada. Exclusive vaccine marketing and distribution agreement in Germany with CSL Seqirus.
Revenue Growth: Total revenues reached EUR 127 million, a 9% increase year-over-year. Product sales increased by 6.2% to EUR 119.4 million.
Operational Efficiency: Operating cash burn significantly reduced, with a cash position of EUR 143.5 million. Gross margin improvements noted for IXIARO and DUKORAL.
Debt Refinancing: Successfully completed debt refinancing with Pharmakon, enhancing financial flexibility.
Focus on Lyme Disease Vaccine: Positioned as the largest growth driver for the company, with expectations of sustained profitability post-approval and commercialization.
Pipeline Development: Advancing internal candidates and exploring external partnerships to build a coherent R&D pipeline.
Geopolitical Risks: The company faced headwinds from geopolitical factors, which could impact operations and financial performance.
Regulatory Challenges: The chikungunya vaccine (IXCHIQ) remains suspended in the United States, awaiting further information from the FDA. This regulatory hurdle has significantly impacted sales in the Travel segment and delayed market expansion.
Foreign Currency Fluctuations: Adverse currency fluctuations negatively impacted revenues, particularly for IXIARO and DUKORAL sales.
Supply Chain and Distribution Transitions: Transitioning from the current distributor to CSL Seqirus in Germany caused lower sales for DUKORAL. Additionally, the anticipated discontinuation of certain third-party distribution agreements led to a decrease in third-party product sales.
R&D and Operational Costs: Increased R&D expenses, particularly for the Shigella vaccine candidate and IXCHIQ Phase IV post-marketing commitments, have contributed to financial strain. Idle capacity costs and provisions for lower IXCHIQ demand also added to operational expenses.
Market Demand and Sales Adjustments: The temporary restriction and U.S. license suspension for IXCHIQ led to lower demand and sales adjustments, impacting overall revenue guidance.
Economic Uncertainty: The company emphasized the need to ensure sufficient cash runway to reach key inflection points, highlighting financial pressures and economic uncertainties.
Lyme Disease Vaccine (VLA15): Pfizer plans to submit regulatory applications in the U.S. and Europe in 2026, with product launch expected in autumn 2027, ahead of the 2028 tick season. The vaccine aims to address a significant unmet medical need, with a favorable health economic benefit.
Chikungunya Vaccine (IXCHIQ): Awaiting further information from the FDA regarding U.S. license suspension. Expansion into LMIC territories is a focus, with post-marketing effectiveness studies commencing in Brazil and other endemic countries.
Shigella Vaccine Candidate (S4V2): Phase II results in infants expected by the end of 2025. Phase IIb pilot efficacy data anticipated in 2026. The program is designed to be capital-efficient and addresses a significant unmet medical need, particularly in LMICs and for travelers.
Financial Guidance for 2025: Product sales projected at EUR 155 million to EUR 170 million, with total revenues of EUR 165 million to EUR 180 million. R&D expenses expected to be EUR 80 million to EUR 90 million, partially offset by grant funding and R&D tax credits. Continued improvement in gross margin and strategic investments into R&D are anticipated.
Midterm Financial Outlook: Valneva expects to achieve sustainable profitability post-approval and commercialization of the Lyme disease vaccine, driven by milestones and royalties starting in late 2027.
The selected topic was not discussed during the call.
The earnings call revealed mixed financial performance, with a significant operating loss and negative EBITDA largely due to the absence of last year's PRV sale. While there were improvements in gross margins, the temporary U.S. license suspension for IXCHIQ and unclear FDA timelines add uncertainty. The Q&A highlighted management's lack of specific guidance on key issues like IXCHIQ's suspension and DUKORAL's growth in Germany, leading to a negative sentiment. The absence of clear guidance and the mixed financial results suggest a likely negative stock price reaction.
The earnings call reveals mixed signals. While there are strong regulatory achievements and promising vaccine developments, the financial performance shows significant operating losses and reduced cash position. Guidance remains steady, but the lack of additional revenue recognition and vague responses in the Q&A highlight uncertainties. The operational cash burn reduction is positive, but overall, the sentiment is balanced by both positive and negative factors, leading to a neutral outlook.
The earnings call presents a mixed picture. While there is strong sales growth and improved cash burn, the financial health is weakened by operating losses and a net loss. The shareholder return plan is neutral, with a share issuance and reduced cash burn. The Q&A section reveals uncertainties, particularly around regulatory risks and unclear guidance on key metrics. Despite strong financial performance, the market strategy faces competition and regulatory challenges. Overall, the sentiment is neutral, with no strong catalysts for significant short-term stock price movement.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
